Trial Profile
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2024
Price :
$35
*
At a glance
- Drugs Iopofosine I 131 (Primary) ; Dexamethasone
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Acronyms CLOVER I; CLOVER-WaM
- Sponsors Cellectar Biosciences
- 01 Apr 2024 This trial has been completed in Czechia, according to European Clinical Trials Database record.
- 27 Mar 2024 According to a Cellectar Biosciences Media Release, study data update is planned for Q2 of 2024.
- 27 Mar 2024 Primary endpoint (Major response rate) has been met, according to a Cellectar Biosciences Media Release.